Background: multiple myeloma (MM) is a malignant neoplasm of plasma cells that accumulate in bone marrow leading to bone destruction and marrow failure. Multiple myeloma accounts for about 1.8% of all cancers and slightly over 17% of all the hematologic malignancies in the United States. It is more common in men and for unknown reasons. Objective: this study aims at analysis the epidemiological data of the patients treated from multiple myeloma at Ain Shams University together with reviewing the different lines of management according to recent recommendations. Patients and Methods: this retrospective analysis of 62 patients with multiple myloma data recorded at their files with follow up and reviews of the recent advances in the management of multiple myeloma. Results: we found that 96.8% of patients showing clinical improvement after treatment on other hand only 3.2% deteriorated, 61.35 of patients were alive, 9.7% died and 29% lost follow up, the mean time to DFS was 22.55 months, mean OS was 63.2 months with 87.8% of patients survived at the end of the study, as regard mean PFS was 54.9 months with PFS at end of study was 74.9% of patients, there was insignificant differences between OS and demographic data, laboratory studies, there was insignificant differences between PFS and demographic data, laboratory studies. Conclusion: Multiple myeloma (MM) is a heterogeneous hematologic malignancy involving the proliferation of plasma cells derived by different genetic events contributing to the development, progression, and prognosis of this disease.